Healthcare Contract Development and Manufacturing Organization are the institutions in the Pharmaceutical industry on a contract basis to offer wide-ranging services starting from drug development through drug manufacturing. This contract allows majority of pharmaceutical companies to outsource those parts of the business, which can support with scalability or can let the major company to emphasize on drug discovery and drug marketing instead. There are various services offered by pre-formulation, stability studies, formulation development, method development, clinical trials, scale-up, formal stability, commercial production and registration batches. The aim of service providers is to concentrate on a specific technology or dosage form and also promote end-to-end continuity and efficiency for all of their outsourcing clients.
COVID-19 scenario analysis:
Coronavirus disease 2019 (COVID-19) is the main cause due to which the forced lockdown is carried out, resulting into great economic loss globally. COVID-19 pandemic has fraught healthcare system globally and developed countries are projected to cause economic downturn. The pandemic has an adversative impact on the healthcare system, resultant in 50% to 70% drop in revenue from March. The small hospitals, clinics and nursing homes, have been asked and enforced to shut their operations. As a result of social distancing reduction in number of elective surgical procedures during the pandemic, in order to avoid the hospital acquired infections. In addition, visa terminations have led to a break in medical tourism and can deleteriously impact the healthcare services market growth.
Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis
The key factor which is anticipated to propel the market includes rise in the demand to outsource various activities which is time consuming by the pharmaceutical industries. The growth in the pharmaceutical industry would help the market grow significantly in the coming years. The rise in the support of CDMOs in dropping the capital and operational expenses would help the market gain maximum revenue in the near future. The surge in the regulatory affairs, which are favorable and quality assurance services are the factors driving the market in the coming years. Furthermore, the higher logistics costs and threat to the infringement to Intellectual Property rights (IP) may hinder the growth of the market in the forecast period.
The global healthcare contract development and manufacturing organization market trends are as follows:
New product launches and expansions to flourish the market
The launch of new products for outsourcing the various processes involved in pharmaceutical industries and the expansion posed by the key market players would propel the market growth in the near future. For instance, October 2019, ANI Pharmaceuticals announced the launch of its own contract development and also manufacturing organization (CDMO). It has named this organization as ANI Global Source which is proposed to be supporting the pharmaceutical industries in late-stage development to commercial manufacture for the small molecule drug products.
Furthermore, in December 2019, Thermo Fisher Scientific Inc. announced that it had opened a new viral vector CDMO, in about USD 90 million in Lexington. It is said that the organization will be able to assist in the development, testing and the manufacturing of viral vectors, which are major parameters for the advancement as new life-saving gene and cell therapies worldwide.
Surge in mergers and acquisitions to boost the market
The growth in the acquisitions and the definitive agreements carried out by the key market leaders are anticipated to help the market grow significantly in the forecast period. For instance, in November 2018, Cambrex had declared that it acquired Avista, which is a contract development and manufacturing organization. It offered a broad range of services ranging from the initial drug development and current good manufacturing processes to microbiology testing, stand-alone and solid state sciences.
In addition, in November 2019, Recipharm, which is a pharmaceutical service firm that is based in Stockholm announced that it will acquire Consort Medical, which is a British supplier of the drug-delivery devices and also offers manufacturing services for approximately $650 million.
Key benefits of the report:
- This study presents the analytical depiction of the global healthcare contract development and manufacturing organization industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global healthcare contract development and manufacturing organization market share.
- The current market is quantitatively analyzed to highlight the global market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed global market analysis based on competitive intensity and how the competition will take shape in coming years.
Questions answered in the healthcare contract development and manufacturing organization market research report:
- Which are the leading market players active in the healthcare contract development and manufacturing organization market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities in the market?
- What are the projections for the future that would help in tasking further strategic steps?
Healthcare Contract Development and Manufacturing Organization Market Report Highlights
| Aspects | Details |
 By Services |
|
 By Region |
|
 Key Market Players | Siegfried Holding AG, Flex, Thermo Fisher Scientific Inc., Covance Inc., Sanmina Corporation, Lonza Group Ltd., IQVIA Holdings Inc., Recipharm AB, Jabil, Catalent Inc |
 Other Players | Bio-Rad Laboratories |
Loading Table Of Content...
